PSTV Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -- compared to Plus Therapeutics's net margin of 5.12%. Plus Therapeutics's return on equity of -- beat InfuSystems Holdings's return on equity of 2.8%.

Plus Therapeutics has a consensus price target of --, signalling upside risk potential of 1371.96%. On the other hand InfuSystems Holdings has an analysts' consensus of -- which suggests that it could grow by 73.31%. Given that Plus Therapeutics has higher upside potential than InfuSystems Holdings, analysts believe Plus Therapeutics is more attractive than InfuSystems Holdings.

Plus Therapeutics has a beta of 0.705, which suggesting that the stock is 29.519% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.528, suggesting its more volatile than the S&P 500 by 52.819%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Plus Therapeutics's net income of -$2.9M is lower than InfuSystems Holdings's net income of $1.8M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 128.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 1.17x versus 1.32x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Plus Therapeutics's net margin of -18.58%. Plus Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Plus Therapeutics has a consensus price target of --, signalling upside risk potential of 1371.96%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Plus Therapeutics has higher upside potential than Retractable Technologies, analysts believe Plus Therapeutics is more attractive than Retractable Technologies.

Plus Therapeutics has a beta of 0.705, which suggesting that the stock is 29.519% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Plus Therapeutics's net income of -$2.9M is lower than Retractable Technologies's net income of -$1.9M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 1.17x versus 0.49x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Plus Therapeutics's net margin of -4291.67%. Plus Therapeutics's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

Plus Therapeutics has a consensus price target of --, signalling upside risk potential of 1371.96%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 476.37%. Given that Plus Therapeutics has higher upside potential than Catheter Precision, analysts believe Plus Therapeutics is more attractive than Catheter Precision.

Plus Therapeutics has a beta of 0.705, which suggesting that the stock is 29.519% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Plus Therapeutics's net income of -$2.9M is higher than Catheter Precision's net income of -$4.1M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 1.17x versus 0.93x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Plus Therapeutics's net margin of -17.98%. Plus Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Plus Therapeutics has a consensus price target of --, signalling upside risk potential of 1371.96%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 458.31%. Given that Plus Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Plus Therapeutics is more attractive than Xtant Medical Holdings.

Plus Therapeutics has a beta of 0.705, which suggesting that the stock is 29.519% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Plus Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Plus Therapeutics's net income of -$2.9M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 1.17x versus 0.47x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.